Richard E. Lowenthal - 02 Jan 2026 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
PRESIDENT AND CEO, Director, 10%+ Owner
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Issuer symbol
SPRY
Transactions as of
02 Jan 2026
Net transactions value
$0
Form type
4
Filing time
05 Jan 2026, 16:19:13 UTC
Previous filing
22 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lowenthal Richard E PRESIDENT AND CEO, Director, 10%+ Owner C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 300, SAN DIEGO /s/ Kathleen Scott, Attorney-in-Fact 05 Jan 2026 0001378550

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock option (right to buy) Award $0 +875,000 $0.000000 875,000 02 Jan 2026 Common Stock 875,000 $11.49 Direct F1
transaction SPRY Stock Option (right to buy) Award $0 +240,000 $0.000000 240,000 02 Jan 2026 Common Stock 240,000 $11.49 By Spouse F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026.